Burkholderia cepacia Infections in Cystic Fibrosis (Burkholderia cepacia)
Overview
Plain-Language Overview
Burkholderia cepacia infections in cystic fibrosis are caused by a group of bacteria that can infect the lungs of people with cystic fibrosis (CF), a genetic disorder affecting the respiratory system. These infections mainly affect the lungs, leading to worsening breathing problems and lung damage. The bacteria are resistant to many common antibiotics, making infections difficult to treat. People with CF who get this infection may experience more frequent lung infections and a faster decline in lung function. The infection can spread between individuals with CF, so it is a serious concern in this population. Early detection and careful management are important to control symptoms and prevent complications.
Clinical Definition
Burkholderia cepacia infections in cystic fibrosis represent a serious opportunistic infection caused by the Burkholderia cepacia complex, a group of closely related gram-negative bacteria. These bacteria colonize the airways of patients with cystic fibrosis, exploiting the thick mucus and impaired mucociliary clearance characteristic of the disease. The infection is associated with increased pulmonary inflammation, accelerated decline in lung function, and can lead to a severe, sometimes fatal, necrotizing pneumonia known as cepacia syndrome. The bacteria exhibit intrinsic resistance to multiple antibiotics, complicating treatment. Transmission occurs via person-to-person contact or contaminated environments, necessitating strict infection control. The presence of this infection often impacts lung transplant eligibility due to poor outcomes.
Inciting Event
Inhalation or aspiration of B. cepacia from contaminated environmental sources or patient-to-patient transmission initiates infection.
Cross-infection during clinic visits or hospital stays is a common trigger for colonization in cystic fibrosis patients.
Disruption of normal airway microbiota by antibiotics facilitates B. cepacia overgrowth.
Latency Period
Variable latency from colonization to symptomatic infection ranges from weeks to months in cystic fibrosis patients.
Chronic colonization may be asymptomatic for prolonged periods before clinical deterioration occurs.
Rapid progression to cepacia syndrome can occur within days to weeks after initial infection in some cases.
Diagnostic Delay
Misidentification of B. cepacia complex due to its phenotypic similarity to other gram-negative rods delays diagnosis.
Low clinical suspicion in early colonization leads to underdiagnosis in cystic fibrosis patients.
Inadequate or infrequent sputum cultures may miss intermittent shedding of B. cepacia.
Delayed recognition of cepacia syndrome due to nonspecific symptoms and overlap with cystic fibrosis exacerbations.
Clinical Presentation
Signs & Symptoms
Chronic productive cough with purulent sputum
Recurrent pulmonary infections and exacerbations of respiratory symptoms
Fever and malaise during acute infection
Increased dyspnea and exercise intolerance
Weight loss and failure to thrive in advanced disease
History of Present Illness
Progressive cough and increased sputum production are common initial symptoms in B. cepacia infection.
Recurrent pulmonary exacerbations with fever and malaise often signal worsening infection.
Rapid decline in lung function and development of necrotizing pneumonia characterize cepacia syndrome.
Systemic symptoms such as weight loss and fatigue may develop with chronic infection.
Past Medical History
Known cystic fibrosis diagnosis with prior chronic lung infections is the primary relevant history.
Previous colonization or infection with Pseudomonas aeruginosa or other resistant organisms increases risk.
History of frequent antibiotic courses and hospitalizations for pulmonary exacerbations.
Prior lung transplantation may predispose to invasive B. cepacia infection.
Family History
Family history of cystic fibrosis due to CFTR mutations is relevant for patient susceptibility.
No direct heritable predisposition to B. cepacia infection outside of cystic fibrosis is established.
Familial clustering of cystic fibrosis lung disease severity may influence infection risk.
Physical Exam Findings
Crackles and wheezing on lung auscultation indicating airway inflammation
Digital clubbing due to chronic hypoxia in cystic fibrosis patients
Tachypnea and increased work of breathing during acute infection
Cyanosis in severe respiratory compromise
Decreased breath sounds in areas of lung consolidation or collapse
Diagnostic Workup
Diagnostic Criteria
Diagnosis is established by isolating Burkholderia cepacia complex from respiratory specimens such as sputum or bronchoalveolar lavage using selective culture media. Identification requires biochemical testing or molecular methods like PCR to differentiate it from other gram-negative bacteria. Repeated positive cultures confirm chronic colonization or infection. Clinical correlation with worsening respiratory symptoms and decline in lung function supports the diagnosis. Antibiotic susceptibility testing is essential due to the organism's multidrug resistance.
Pathophysiology
Key Mechanisms
Chronic pulmonary colonization by Burkholderia cepacia complex leads to persistent airway inflammation and progressive lung damage in cystic fibrosis.
Biofilm formation by B. cepacia enhances resistance to antibiotics and host immune defenses, promoting chronic infection.
Endotoxin release from B. cepacia triggers intense neutrophilic inflammation and tissue injury in the lungs.
Multidrug resistance mechanisms in B. cepacia complicate eradication and contribute to treatment failure.
Epithelial cell invasion by B. cepacia facilitates persistence and dissemination within the respiratory tract.
| Involvement | Details |
|---|---|
| Organs | Lungs are the main organ affected, with chronic infection causing bronchiectasis and respiratory failure. |
Sinuses may serve as reservoirs for persistent infection in cystic fibrosis patients. | |
| Tissues | Pulmonary tissue is the primary site of infection and inflammation leading to progressive lung damage. |
Mucosal tissue in the airways is disrupted by chronic colonization and biofilm formation. | |
| Cells | Neutrophils play a central role in the inflammatory response to Burkholderia cepacia infection in cystic fibrosis lungs. |
Macrophages contribute to bacterial clearance and cytokine production during infection. | |
Epithelial cells of the respiratory tract are damaged by chronic infection and inflammation. | |
| Chemical Mediators | Interleukin-8 (IL-8) is elevated and recruits neutrophils to the site of infection. |
Tumor necrosis factor-alpha (TNF-α) mediates inflammation and tissue damage in infected lungs. | |
Reactive oxygen species (ROS) produced by neutrophils contribute to bacterial killing and lung injury. |
Treatments
Pharmacological Treatments
Ceftazidime
- Mechanism:
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins
- Side effects:
Allergic reactions
Gastrointestinal upset
Nephrotoxicity
- Clinical role:
First-line
Trimethoprim-sulfamethoxazole
- Mechanism:
Inhibits sequential steps in bacterial folate synthesis, leading to bactericidal activity
- Side effects:
Rash
Hyperkalemia
Bone marrow suppression
- Clinical role:
First-line
Meropenem
- Mechanism:
Binds to penicillin-binding proteins, inhibiting bacterial cell wall synthesis
- Side effects:
Seizures
Hypersensitivity reactions
Gastrointestinal upset
- Clinical role:
Second-line
Tobramycin
- Mechanism:
Binds to 30S ribosomal subunit, inhibiting bacterial protein synthesis
- Side effects:
Nephrotoxicity
Ototoxicity
Neuromuscular blockade
- Clinical role:
Adjunctive
Non-pharmacological Treatments
Regular airway clearance techniques including chest physiotherapy to improve mucus clearance.
Strict infection control measures to prevent cross-infection among cystic fibrosis patients.
Nutritional support to maintain optimal body weight and immune function.
Prevention
Pharmacological Prevention
Chronic suppressive antibiotic therapy tailored to susceptibility patterns
Inhaled antibiotics such as tobramycin to reduce bacterial load
Early aggressive intravenous antibiotics during exacerbations
Use of mucolytics and airway clearance agents to prevent infection
Avoidance of broad-spectrum antibiotics that promote resistance
Non-pharmacological Prevention
Strict infection control measures including patient segregation to prevent cross-infection
Regular airway clearance techniques such as chest physiotherapy
Routine sputum surveillance cultures to detect early colonization
Avoidance of exposure to contaminated water or hospital environments
Nutritional support to maintain immune function and lung health
Outcome & Complications
Complications
Cepacia syndrome, a rapidly progressive necrotizing pneumonia with sepsis
Respiratory failure due to progressive lung damage
Lung transplantation rejection risk increased by Burkholderia cepacia colonization
Multidrug-resistant infections complicating treatment
Chronic inflammation leading to bronchiectasis progression
| Short-term Sequelae | Long-term Sequelae |
|---|---|
|
|
Differential Diagnoses
Burkholderia cepacia Infections in Cystic Fibrosis (Burkholderia cepacia) versus Pseudomonas aeruginosa Infection
Burkholderia cepacia Infections in Cystic Fibrosis (Burkholderia cepacia) | Pseudomonas aeruginosa Infection |
|---|---|
Gram-negative rod with variable pigmentation, often yellow-green, and distinct cepacia complex species | Gram-negative rod with characteristic blue-green pigment and fruity odor |
Often resistant to multiple antibiotics including aminoglycosides and polymyxins, requiring combination therapy | Typically sensitive to antipseudomonal beta-lactams and aminoglycosides |
Can cause rapid deterioration known as cepacia syndrome with necrotizing pneumonia and sepsis | Chronic colonization with gradual lung function decline |
Burkholderia cepacia Infections in Cystic Fibrosis (Burkholderia cepacia) versus Staphylococcus aureus Infection
Burkholderia cepacia Infections in Cystic Fibrosis (Burkholderia cepacia) | Staphylococcus aureus Infection |
|---|---|
Gram-negative bacilli, oxidase positive | Gram-positive cocci in clusters, catalase and coagulase positive |
More frequent in older children and adults with cystic fibrosis | Common in young children with cystic fibrosis |
Often multidrug resistant, requiring tailored antibiotic regimens | Usually sensitive to anti-staphylococcal agents like nafcillin or vancomycin |
Burkholderia cepacia Infections in Cystic Fibrosis (Burkholderia cepacia) versus Non-tuberculous Mycobacterial (NTM) Infection
Burkholderia cepacia Infections in Cystic Fibrosis (Burkholderia cepacia) | Non-tuberculous Mycobacterial (NTM) Infection |
|---|---|
Non-acid-fast gram-negative rods on culture | Acid-fast bacilli positive on sputum smear and culture |
Potential for acute necrotizing pneumonia and rapid decline | Chronic indolent pulmonary infection with nodular bronchiectasis |
Requires combination antibiotics targeting resistant gram-negative bacteria | Requires prolonged multidrug antimycobacterial therapy |
Burkholderia cepacia Infections in Cystic Fibrosis (Burkholderia cepacia) versus Aspergillus fumigatus Colonization or Infection
Burkholderia cepacia Infections in Cystic Fibrosis (Burkholderia cepacia) | Aspergillus fumigatus Colonization or Infection |
|---|---|
Gram-negative bacterial rods on culture | Fungal hyphae seen on microscopy and culture |
No eosinophilia; neutrophilic inflammation predominates | Often associated with allergic bronchopulmonary aspergillosis and eosinophilia |
Negative fungal serologies; positive bacterial cultures | Positive serum IgE and precipitins against fungal antigens |